Evidence map›Paper›PMID 42733437›Full record

ArticleJournal of student research2022

Deep Neural Network Classifier for Alzheimer's Disease.

Jason Lin, Hayan Lee, Michael Snyder

Abstract read
In one paragraph

Article in Journal of student research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jason LinEvergreen Valley High School, San Jose, CA, USA.
Hayan LeeEvergreen Valley High School, San Jose, CA, USA.
Michael SnyderEvergreen Valley High School, San Jose, CA, USA.

Funding

PRODUCTION CENTER FOR MAPPING REGULATORY REGIONS OF THE HUMAN GENOMEUM1HG009442 · NHGRI · STANFORD UNIVERSITY · PI SNYDER, MICHAEL P. · 2017 to 2021
$20.1M
NHGRI NIH HHS UM1 HG009442
6 · The paper itself

Abstract

Alzheimer's disease (AD) is a neurodegenerative disease characterized by dementia and, eventually, a loss of cognitive abilities. Two histopathological features are associated with AD, neurofibrillary tangles, and amyloid-beta plaque. Both contribute to neuron cell death, neuron dysfunction, and AD pathogenesis. Current methods to diagnose AD remain reliant on symptomatic diagnosis with interviews that can be time-consuming, costly, and inaccurate. Alternative methods such as brain imaging are expensive and require extensive laboratory setup for accurate results. Thus molecular-level quantitative approaches are necessary. Omics datasets and machine learning technology advancements have opened new avenues to diagnose AD. This paper proposes using statistical methods such as principal component analysis, t-distributed stochastic neighbor embedding, and Kolmogorov-Smirnov test combined with Benjamini-Hochberg correction through feature selection and dimensionality reduction to isolate significant features associated with AD. Furthermore, we developed machine learning models based on logistic regression, random forest classifier, and deep neural network (DNN) classifier to predict AD diagnosis. Eight unique genes (TGM2, NKIRAS1, SYK, GABARAPL2, ABCC12, NDEL1, TEP1) were identified as significant biomarkers of AD and confirmed previous works identifying prognoses' roles in AD. After extensive hyperparameter tuning, the DNN model showed the best prediction performance for AD diagnosis among the three machine learning algorithms. The DNN model and preprocessed dataset demonstrated a 5-fold cross-validation accuracy of 0.823 and AUC-ROC of 0.940. Its code is publicly available at https://www.kaggle.com/neobrando/ml-dnn.

Identifiers

PMID42733437
PMCPMC13571259

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.